Drug recall · August 31, 2016
Amoxicillin for Oral Suspension USP recall
Why: Superpotent drug: Out of specification test result for assay during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76
- Lots / codes
Lot # 35434158A, Exp 6/17
- Quantity
- 53,328 bottles
- Company
- Teva North America, Horsham, PA
- Distribution
- Nationwide
- Initiated
- June 24, 2016 · Voluntary: Firm initiated
- Classified
- August 24, 2016
- Reported
- August 31, 2016
- Ended
- February 7, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amoxicillin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.